REFERENCES
- Brin Mitchell, F., Blitzer, A., Fahn, S., Gould, W., & Lovelace, R. E. (2004). Adductor laryngeal dystonia (spastic dysphonia): Treatment with local injections of botulinum toxin (Botox). Movement Disorders, 4, 287–296.
- Epstein, R., Stygall, J., & Newman, S. (1997). The short-term impact of Botox injections on speech disability in adductor spasmodic dysphonia. Disability and Rehabilitation, 19, 20–25.
- Ghorayeb, I., & Burbaud, P. (2009). Failure of botulinum toxin A to relieve restless legs syndrome. Sleep Medicine, 10, 394–395.
- Hening, W. (2007). Current guidelines and standards of practice for restless legs syndrome. The American Journal of Medicine, 120, S22–S27.
- Kushida, C. (2006). Botulinum toxin A: New hope for RLS? Journal of Clinical Sleep Medicine, 2, 279–280.
- Nahab, F., Peckham, E., & Hallett, M. (2008). Double-blind, placebo-controlled, pilot trial of botulinum toxin type A in restless leg syndrome. Neurology, 71, 950–951.
- Naumanna, M., Albaneseb, A., Heinenc, F., Molenaersd, G., & Reljae, M. (2006). Safety and efficacy of botulinum toxin type A following long-term use. European Journal of Neurology, 13, S35–S40.
- Rotenberg, J., Canard, K., & DiFazio, M. (2006). Successful treatment of recalcitrant restless legs syndrome with botulinum toxin type-A. Journal of Clinical Sleep Medicine, 2, 279–280.
- Schapira, A. (2004). Restless legs syndrome: An update on treatment options. Drugs, 64, 149–158.
- Tergau, F., Wischer, D., & Paulus, W. (1999). Motor system excitability in patients with restless legs syndrome. Neurology, 51, 1060–1063.